Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder (OCDDRUG)
Primary Purpose
SSRI-Refractory Obsessive-Compulsive Disorder
Status
Completed
Phase
Phase 4
Locations
Japan
Study Type
Interventional
Intervention
atypical antipsychotic drug
exposure response prevention
Sponsored by
About this trial
This is an interventional trial for SSRI-Refractory Obsessive-Compulsive Disorder focused on measuring obsessive-compulsive disorder, augmentation treatment, SSRI-refractory
Eligibility Criteria
Inclusion Criteria:
- Male or female, 18 years of age or over
- Patients were diagnosed as having obsessive-compulsive disorder by the Structured Clinical Interview for DSM-IV Patient version (SCID-P)
- They received standardized treatment for at least 1 year at the OCD clinic in our university hospital.
- Each subject gave written informed consent to take part after receiving a complete description of this study.
- All subjects were free of medical illness based on results of physical examination and screening tests of blood and urine, and no subjects received any lipid lowering or hypoglycemic agent during the 1-year study period.
Exclusion Criteria:
- Current clinically significant medical conditions such as diabetes
Sites / Locations
- Dept of Neuropsychiatry, Osaka City University, graduate School of Medicine
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
CBT
1
2
Arm Description
All subjects received cognitive-behavioral therapy (CBT) during the study period.
Drug; Paroxetine (30-50mg/D)or Fluvoxamine (150-250mg/D), 1-year administration
Either risperidone (1-5mg/D), olanzapine (1-5mg/D) or quetiapine (25-100mg/D) was added to ongoing SSRI, the combination trial was continued at least for half a year.
Outcomes
Primary Outcome Measures
Yale-Brown Obsessive-Compulsive Scale
Secondary Outcome Measures
yale-Brown Obsessive-Compulsive Scale
BMI, TG, T-CHO, FBS
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00854919
Brief Title
Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder
Acronym
OCDDRUG
Official Title
An Long Term Trial on Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder
Study Type
Interventional
2. Study Status
Record Verification Date
December 2005
Overall Recruitment Status
Completed
Study Start Date
January 2006 (undefined)
Primary Completion Date
December 2007 (Actual)
Study Completion Date
December 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Osaka City University
4. Oversight
5. Study Description
Brief Summary
Objective: Although atypical antipsychotic drugs (AAPDs) have been found effective in the augmentation of serotonin reuptake inhibitors (SRIs) for treatment-resistant obsessive-compulsive disorder (OCD) in short terms trials, there are few data on the effectiveness and safety of these agents in clinical settings over the long term.
Method: Subjects (n=46) who responded to selective SRIs (SSRIs) in an initial 12-week trial were continued on SRI-monotherapy plus cognitive-behavioral therapy (CBT) for one year. Subjects (n=44) who failed to respond to SSRIs were randomly assigned to one of 3 AAPDs such as risperidone and were consecutively treated using SSRI+AAPD combined with CBT for a year.
Detailed Description
More recently, second-generation atypical antipsychotic drugs (AAPD) that modulate both 5-HT and DA function, such as risperidone (RIS), olanzapine (OLZ) and quetiapine (QET), have been found effective in the augmentation of SSRIs for treatment-resistant OCD.
Nevertheless, the AAPDs have been associated with common and serious adverse effects, such as body weight (BW) gain and metabolic dysregulation. Metabolic dysregulation includes glucoregulatory dysfunction and dyslipidemia. Indeed, studies of some AAPD in SSRI-refractory OCD patients have similarly reported significant BW gain. AAPD-induced BW gain may influence patients' adherence to medication and places them at risk for a broad range of medical problems.
Most work on AAPDs in treatment-refractory OCD has been conducted in the form of short-term efficacy studies. There have been fewer studies of the effectiveness, safety, and tolerability of these agents in the context of a clinic where CBT is also provided, and where treatment is continued for a significant period of time. In the current effectiveness study, we sought to examine the response of SSRI-refractory patients to augmentation with AAPDs, comparing adverse events in such compared to a control group of SSRI responders.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
SSRI-Refractory Obsessive-Compulsive Disorder
Keywords
obsessive-compulsive disorder, augmentation treatment, SSRI-refractory
7. Study Design
Study Phase
Phase 4
8. Arms, Groups, and Interventions
Arm Title
CBT
Arm Type
Experimental
Arm Description
All subjects received cognitive-behavioral therapy (CBT) during the study period.
Arm Title
1
Arm Type
Experimental
Arm Description
Drug; Paroxetine (30-50mg/D)or Fluvoxamine (150-250mg/D), 1-year administration
Arm Title
2
Arm Type
Active Comparator
Arm Description
Either risperidone (1-5mg/D), olanzapine (1-5mg/D) or quetiapine (25-100mg/D) was added to ongoing SSRI, the combination trial was continued at least for half a year.
Intervention Type
Drug
Intervention Name(s)
atypical antipsychotic drug
Intervention Description
For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
Intervention Type
Behavioral
Intervention Name(s)
exposure response prevention
Intervention Description
After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
Primary Outcome Measure Information:
Title
Yale-Brown Obsessive-Compulsive Scale
Time Frame
1 year
Secondary Outcome Measure Information:
Title
yale-Brown Obsessive-Compulsive Scale
Time Frame
1 year
Title
BMI, TG, T-CHO, FBS
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female, 18 years of age or over
Patients were diagnosed as having obsessive-compulsive disorder by the Structured Clinical Interview for DSM-IV Patient version (SCID-P)
They received standardized treatment for at least 1 year at the OCD clinic in our university hospital.
Each subject gave written informed consent to take part after receiving a complete description of this study.
All subjects were free of medical illness based on results of physical examination and screening tests of blood and urine, and no subjects received any lipid lowering or hypoglycemic agent during the 1-year study period.
Exclusion Criteria:
Current clinically significant medical conditions such as diabetes
Facility Information:
Facility Name
Dept of Neuropsychiatry, Osaka City University, graduate School of Medicine
City
Osaka
ZIP/Postal Code
545-8585
Country
Japan
12. IPD Sharing Statement
Citations:
PubMed Identifier
19422759
Citation
Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2009 Jun;70(6):863-8. doi: 10.4088/JCP.08m04369. Epub 2009 May 5.
Results Reference
derived
Learn more about this trial
Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder
We'll reach out to this number within 24 hrs